The Main Differences Between MDA And MDMA
Last reviewed and updated: June 19, 2026.
Key Takeaways
| Key pharmacological difference | MDA has more psychedelic effects (5-HT2A agonism); MDMA more entactogenic (empathy/connection); MDA lasts 6–10 hrs vs MDMA 3–5 hrs |
| Risk comparison | MDA generally carries higher risk: more unpredictable dose-response, longer adverse-effect duration, higher neurotoxicity potential at high doses |
| MDMA clinical status | MAPS Phase 3: 67% vs 32% PTSD remission; FDA rejected application Aug 2024 (methodological concerns); additional trials ongoing; approval likely 2028–2029+ |
| MDA clinical status | No active clinical trial program; limited formal research; Australia approved MDMA (not MDA) for therapeutic use in 2023 |
| Harm reduction | Reagent testing can distinguish MDA from MDMA; always use fentanyl test strips separately; never combine either with MAOIs |
Both MDA and MDMA belong to the phenethylamine class of drugs. This category also includes psychedelics like mescaline and 2CB. The chemist Alexander Shulgin, known as the “godfather of ecstasy“, actually first started synthesizing molecules like MDMA after trying mescaline. He described the process of synthesizing various phenethylamine compounds (and his experiences with them) in the book PiKHAL (1990), which stands for Phenethylamines I Have Known and Loved.
Both MDA and MDMA have a phenethylamine backbone. This is a molecule containing a hexagonal ring of carbons — a “benzene ring” — to which is attached a side chain, made up of two carbon atoms and an amine group (a nitrogen attached to two hydrogen atoms). Phenethylamine occurs in nature, such as the human body, in small amounts. It is a stimulant in humans.
Interested in joining a Psychedelics Clinical Trial? Sign up here now and we will connect you with a clinical trial in your area when one becomes available.
As phenethylamines, MDA and MDMA share similarities. Like other phenethylamines, they have stimulating effects. Also, in chemical structure, the compounds are quite similar, so their effects can resemble each other in many ways.
However, there are many crucial differences between MDA and MDMA, which you should be aware of.
RELATED: Tuesday Blues: What To Expect After An MDMA Experience
MDA And MDMA Are Known By Different Names
MDMA is known by different names, depending on the country the user is from. It is also called ecstasy, molly, E, X, pingers, and the love drug. Some people also call MDA the “love drug” — but its more common names are Sally, Sass, and Sassafras.
These names refer to the fact that MDA, like MDMA, comes from the oil of the sassafras plant in the illicit manufacturing of the drug.
The Chemical Difference Between MDA And MDMA
Let’s begin with the most obvious difference between MDA and MDMA: the chemical structure. MDA is 3,4-Methylenedioxyamphetamine while MDMA is 3,4-Methylenedioxymethamphetamine. MDA, then, lacks the methyl group that MDMA has, which is attached to the nitrogen atom.
In a chapter in Julie Holland’s 2001 book Ecstasy: The Complete Guide, renowned chemist David Nichols writes the following.
“The methyl group does not profoundly change the chemical properties or the base strength of MDMA when compared with MDA. It does have consequences in terms of the biological effects, however. First, adding a methyl group to the nitrogen atom makes the molecule more lipid (fat) soluble. This means that because the brain is made largely of lipids, MDMA has a greater solubility in brain tissue. In general, drugs that have greater solubility in lipids and an action in the brain also have a faster onset of action but a shorter duration of action. Based only on this observation, one could predict that MDMA should produce its effects faster than MDA but have a shorter action than MDA. This is in fact what is observed.”
Nonetheless, the chemical difference between the two drugs does not result in only this variation in effects.
Nichols adds that the MDMA molecule is, “too large to fit comfortably into the brain serotonin 5-HT2A receptor that is responsible for LSD-like actions. That receptor is only minimally activated by MDMA; hence MDMA lacks significant LSD-like effects.”
RELATED: Champagne & MDMA? Multiple Recalls After Spiked Bottles Of Moët Found
MDA And MDMA Have Different Subjective Effects
Both MDA and MDMA are empathogens or entactogens. This means they tend to induce feelings of empathy, emotional openness, close interpersonal connection, and affection. Yet they are not empathogens to the same degree.
Moreover, as Nichols already states from the quote above, MDMA is not very psychedelic in nature. This contrasts with MDA, which has more psychedelic effects.
Let’s now summarize the main differences between the subjective effects of these two drugs.
MDMA Is More Empathogenic Than MDA
Many people find that MDMA offers a more empathogenic experience than MDA. This means when you take MDMA, you are more likely to have the following.
- A “loved up” feeling, which can make you feel close to — and affectionate toward — people (including total strangers)
- Feelings of sociability and talkativeness
- Open, honest, and heartfelt conversations with others
- Empathy toward others
MDA Is More Psychedelic Than MDMA
Due to the fact that MDA can more easily bind to 5-HT2A receptors, as Nichols points out, this drug tends to have more psychedelic effects compared to MDMA.
Most noticeably, MDA is more likely to produce visual effects. These include the below.
- Visual acuity enhancement
- Color enhancement
- Tracers
- After images
- Seeing geometric patterns
- Visual hallucinations (in high to heavy doses)
The American chemist and pharmacologist Gordon Alles first discovered the psychoactive effects of MDA on July 16, 1930, when he ingested the drug as a form of self-experimentation. He describes the following visual effects.
“Forty-five minutes after the second dosage, an abundance of curling gray smoke rings was readily observed in the environment whenever a relaxed approach to subjective observation was used. Perceptually, these had complete reality. It seemed quite unnecessary to test their properties because it was at the same time surely known and fully appreciated that the source of the visual phenomena could not be external to the body. Concentration of attention on the details of the gray curling forms, by trying to note how they would be affected by passing a finger through their apparent field, caused them to melt away with the fixing of attention.”
MDMA can have visual effects, but you would need a higher dose to experience them. Many users also find that the MDMA experience becomes more psychedelic when combining it with cannabis.
However, you should be aware that this combination may also lead to confusion, anxiety, paranoia, and a state of mind known as “goldfish memory”. This is where someone ends up forgetting what they are talking about or what they meant to be doing.
MDA Is More Stimulating Than MDMA
Another difference between MDA and MDMA is that many people find the former to be more stimulating, providing them with greater energy levels. So while MDMA can make you feel content to sit comfortably, talk with others, and listen to music, MDA may make you want to move around and dance more.
This is how many people view MDMA, especially when in the form of pills at clubs. These pills may also contain speed (amphetamine), which has strong stimulating effects.
The Effects Of MDA Last Longer Than Those Of MDMA
Nichols underscored one important difference between MDA and MDMA: the effects of the former tend to last longer than the latter. An MDMA experience can last 3-6 hours, whereas an MDA experience can last 5-8 hours. For this reason, when taking MDA, be sure to prepare for a longer experience.
The difference in duration between MDA and MDMA also means you may not need to redose if you take MDA.
RELATED: What Is Molly (MDMA) Powder?
Therapeutic Applications
Due to its strong empathogenic effects, MDMA can be useful as a tool in the treatment of post-traumatic stress disorder (PTSD).
Patients with PTSD often have underlying trauma(s) that can be incredibly difficult to confront. These patients may have triggers that can cause memories of the trauma to resurface, leading to states of extreme distress.
For this reason, patients may avoid situations that may trigger their traumatic memories, which can end up impairing their ability to function and engage in normal activities. Traumatic memories can also manifest in the form of nightmares.
MDMA can help people with PTSD and treatment-resistant PTSD (where no other treatments have proved effective), as the drug can reduce anxiety and lower people’s defenses. The drug also allows patients to examine their traumatic memories with reduced fear, as well as speak openly about them and feel increased empathy toward themselves.
Finally, MDMA also heightens levels of oxytocin (the “love hormone”), with many believing it to be responsible for the prosocial and emotional bonding effects of the drug. This can help a patient trust a psychotherapist and be open to discussing their trauma with him or her.
MDMA Therapy’s Legal Status
Due to the effectiveness of MDMA therapy, the Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for this treatment. This is a recognition that the drug may provide more substantial improvements for patients with a serious condition than available therapies.
This designation is also designed to speed up the development and review of the drug treatment. MDMA therapy is predicted to be legal by 2023.
In contrast, MDA is not being scientifically investigated as a tool for psychotherapy. In the 1960s, researchers like Claudio Naranjo, Richard Yensen, and Shulgin believed that MDA could facilitate psychotherapy. And studies in the 1970s did, indeed, find that MDA-assisted psychotherapy could reduce depression, anxiety, and obsessive-compulsive traits in neurotic patients.
However, MDA-assisted psychotherapy has not been studied and promoted like MDMA therapy has been in the past decade.
This is not to say that MDA cannot produce therapeutic and meaningful experiences. Many anecdotal reports also suggest it can.
Scientific Studies
Following on from the last point, scientific studies on MDA are limited, especially when compared to MDMA.
In 2010, a double-blind, placebo-controlled study found that MDA may lead to mystical-type experiences, as well as changes to visual perception. For example, the researchers discovered that MDA produced a significant increase in closed-eye visions (CEVs), with considerable individual variation.
Another double-blind, placebo-controlled study from 2019, compared MDA to MDMA. Researchers discovered many of the differences between the two drugs we have already highlighted. MDA effects shared features with MDMA as well as classic psychedelics, and MDA effects remained at the eight-hour mark while those of MDMA resolved after six hours.
In contrast, there is a wealth of research on MDMA, not just as an adjunct to psychotherapy, but also in terms of the drug’s safety and long-term effects.
MDA And MDMA Differ In Their Popularity
Many researchers have wanted to understand the long-term effects of MDMA because it is a highly popular recreational drug. MDA is available in the illicit drug market but not to the same extent as MDMA.
This would make sense if we compare the subjective effects of the two drugs.
MDMA lasts a shorter amount of time, it’s less psychedelic, and it produces stronger empathogenic effects. In comparison to MDA, people also more commonly combine MDMA with psychedelics. This is known as hippie flipping, which is when shrooms are used, and, as candy flipping, when LSD is used.
Disclaimer: We do not endorse the illicit use of Schedule 1 psychedelic compounds in a non-therapeutic setting. We do, however, hope the regulations look at the research to understand how these drugs can used in powerfully positive ways.
MDA and MDMA in Clinical Research: Where Things Stand in 2025
Both MDA and MDMA have accumulated significant research attention since this article was written, though on very different trajectories. Here’s an update on where each compound stands in formal research and what it means for how we understand their differences.
MDMA: the FDA review and what comes next. MDMA-assisted therapy for PTSD completed two Phase 3 trials under the MAPS research program. The results were compelling — roughly 67% of MDMA-AT participants no longer met PTSD diagnostic criteria after treatment, compared to 32% for placebo (MAPP1 trial). However, the FDA rejected the initial application in August 2024, citing methodological concerns including functional unblinding (trial participants could generally tell whether they received MDMA or placebo, which complicates the interpretation of self-reported outcomes) and concerns about therapist-participant dynamics. MAPS is conducting additional trials with modified protocols. The regulatory path to MDMA-AT approval in the U.S. has extended significantly — likely at minimum 2028–2029 at the current pace.
MDA in formal research: a different path. While MDMA has dominated the clinical trial landscape, MDA has received comparatively little formal research attention. This is partly because MDA’s psychedelic properties make it harder to study in a classical double-blind design (the visual and sensory effects are more pronounced than with MDMA, making blinding even more difficult), and partly because the research community has focused its resources on the compound (MDMA) with the most established clinical track record. What research does exist suggests MDA has a longer duration of action than MDMA (6–10 hours vs. MDMA’s 3–5 hours for comparable doses), more pronounced serotonergic hallucinogenic effects, and potentially greater serotonin neurotoxicity risk at higher doses. The relative risk profile between MDA and MDMA at therapeutic dose ranges has not been formally established in human clinical trials.
Practical harm reduction distinctions. For harm reduction purposes, several differences between MDA and MDMA matter in practice: MDA is less predictable in dose-response at street doses (its effects can be more unpredictable, particularly in polydrug contexts); MDA’s longer duration means any adverse effects are also more prolonged; MDA is less commonly found in tested drug samples at harm reduction events, making adulterant testing more important. Reagent testing (Marquis, Mecke) can help distinguish MDA from MDMA — the two compounds produce slightly different color reactions — which is useful at events where pill presses sometimes contain one when labeled as the other.
Frequently Asked Questions
What are the main differences between MDA and MDMA?
Both are phenethylamine empathogenic compounds in the same chemical family, but with key differences: MDA has a more pronounced psychedelic/hallucinogenic effect profile (due to greater direct serotonin 2A receptor agonism), while MDMA produces more entactogenic (empathy- and connection-enhancing) effects with less perceptual alteration at typical doses. MDA has a longer duration of action (6–10 hours) compared to MDMA (3–5 hours). MDA is generally considered to have a higher neurotoxicity risk profile, particularly at higher doses. Both are Schedule I in the U.S. and most countries globally.
Is MDA more dangerous than MDMA?
MDA carries a generally higher risk profile than MDMA for several reasons: more pronounced and less predictable dose-response at typical street doses; longer duration meaning adverse effects persist longer; greater potential for serotonin neurotoxicity at higher doses based on preclinical evidence; less established harm reduction dosing guidance due to less research. MDMA itself is not safe — it carries real risks including hyperthermia, serotonin syndrome risk in combination with other serotonergic drugs, and cardiovascular effects. MDA amplifies most of these concerns rather than introducing entirely different ones. Neither should be combined with MAO inhibitors or other serotonergic drugs, and neither should be used in conditions affecting cardiovascular health.
Are MDA and MDMA treated the same legally?
Yes, in most jurisdictions. Both MDA and MDMA are Schedule I controlled substances in the United States under the Controlled Substances Act. The same classification applies in most countries under international conventions. Neither compound is legally available for therapeutic or recreational use in the U.S. outside of formal research protocols. MDMA has been the subject of significant regulatory attention due to the MAPS clinical trial program; MDA has not been the subject of comparable regulatory proceedings. Australia’s Therapeutic Goods Administration approved MDMA for therapeutic use under psychiatrist supervision in 2023 — no equivalent approval exists for MDA.
How can you tell MDA and MDMA apart with reagent testing?
Reagent testing can distinguish between MDA and MDMA with reasonable reliability. The Marquis reagent test (sulfuric acid + formaldehyde) produces purple-to-black for MDMA and dark purple for MDA — the colors are similar but distinguishable by a trained eye. The Mecke reagent (ethanol + selenious acid + sulfuric acid) produces a blue-green for MDMA and also responds to MDA. Running multiple reagent tests together increases confidence. For more precise identification, fentanyl test strips should also be used as a separate harm reduction step — adulterant contamination with dangerous compounds is a significant concern with any unregulated street drug. Reagent testing identifies the likely presence of a compound but does not indicate dose or purity.
